摘要
Enormous efforts were focused on the 3-descladinosyl erythromycin derivatives which led to 3-keto (ketol-ides), 3-O-acyl (acylides), 3-O-carbamate (carbamolides), and 3-O-alkyl (alkylides) and cladinosyl-containing erythromycin derivatives such as 4″-O-acyl, 4″-O-carbamate, and 4″-O-alkyl derivatives as recently exemplified by macrolones (macrolide-quinolone hybrids). Ketolides acquire activity against MLSB-resistant pathogens via a featured arylalkyl extension suspended on the macrolide core, which interacts with a base pair formed by A752Ec and U2609Ec located in the nascent peptide release tunnel of the bacterial rRNA. A base pair formed by C2610Ec and G2505Ec probably is another novel binding site for 3-descladinosyl non-ketolides. It is believed that 4″-derived compounds perhaps interfere with the formation of polypeptide because the extension oriented into peptidyl transferase center (PTC) region. Although macro-lones are hybrids of macrolides and quinolones, they do not have dual modes of action, and serve only as protein synthesis inhibitors.
源语言 | 英语 |
---|---|
页(从-至) | 3131-3164 |
页数 | 34 |
期刊 | Current Topics in Medicinal Chemistry |
卷 | 13 |
期 | 24 |
DOI | |
出版状态 | 已出版 - 2013 |